| Status | In progress |
| Process | STA 2018 |
| ID number | 1109 |
Provisional Schedule
| Committee meeting: 1 | 28 August 2019 |
| Expected publication | 20 November 2019 |
Project Team
| Project lead | Jeremy Powell |
Email enquiries
- If you have any queries please email TACommB@nice.org.uk
| Evidence Review Group / Assessment Group | Kleijnen Systematic Reviews Ltd |
Consultees
| Companies sponsors | Zogenix International |
| Others | Department of Health and Social Care |
| NHS Central London CCG | |
| NHS England | |
| NHS West Leicestershire CCG | |
| Welsh Government | |
| Patient carer groups | Brain and Spine Foundation |
| Disability Rights UK | |
| Dravet Syndrome UK | |
| Epilepsy Action | |
| Epilepsy Society | |
| Joint Epilepsy Council | |
| Leonard Cheshire Disability | |
| Muslim Council of Britain | |
| Neurological Alliance | |
| S.T.A.B.L.E (Supporting those affected by Lifelong Epilepsy) | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| SUDEP Action | |
| The Brain Charity | |
| Young Epilepsy | |
| Professional groups | Association of British Neurologists |
| British Neuropathological Society | |
| British Paediatric Neurology Association | |
| Epilepsy Nurses Association | |
| Epilepsy Society | |
| Institute of Neurology | |
| International League Against Epilepsy UK | |
| Neuromodulation Society of UK and Ireland | |
| Primary Care Neurology Society | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Paediatrics and Child Health | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| United Kingdom Clinical Pharmacy Association |
Commentators
| Associated public health groups | Public Health England |
| Public Health Wales | |
| Comparator companies | Accord Healthcare (clobazam, topiramate) |
| Atnahs Pharma UK (clobazam) | |
| Aurobindo Pharma - Milpharm (topiramate) | |
| Biocodex (stiripentol) | |
| Desitin Pharma (sodium valproate) | |
| Janssen (topiramate) | |
| Martindale Pharma (clobazam) | |
| Mylan (topiramate) | |
| Rosemont Pharmaceuticals (clobazam) | |
| Sandoz (topiramate) | |
| Sanofi (clobazam, sodium valproate) | |
| Thame Laboratories (clobazam) | |
| Wockhardt UK (sodium valproate) | |
| Zentiva (sodium valproate) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| Allied Health Professionals Federation | |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Epilepsy Wales | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare Products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| Neurological Alliance of Scotland | |
| NHS Alliance | |
| NHS Confederation | |
| Scottish Medicines Consortium | |
| Wales Neurological Alliance | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | British Neurological Research Trust |
| Cochrane Epilepsy Group | |
| Epilepsy Research UK | |
| MRC Clinical Trials Unit | |
| National Institute for Health Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 January 2019 | Invitation to participate |
| 03 January 2019 | In progress, The appraisal was referred to NICE. |
| 26 July 2018 - 23 August 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance